| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: FVRL |
| Security Type |
Common Stock |
| Lead Underwriter |
Bear Stearns & Co Inc |
| Days In Registration |
300 |
| Date Filed |
8-Apr-2004 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
Favrille Inc, headquartered in San Diego, California, is a biopharmaceutical company focused on the development and commercialization of patient-specific immunotherapies for the treatment of cancer and other diseases of the immune system. The company was incorporated in Delaware in January 2000. |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
20.02M |
| Contact |
- |
| Number of Employees |
151 |
|
| Original Filing Information |
| US |
| Shares Filed |
6.0M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
6.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
900.0K |
| File Amount |
$78.0M |
| File Price Range |
$14.00 - $12.00 |
| File Mid Price |
$13.00 |
Current Filing Information
(Amended 2-Feb-2005) |
|
US |
|
Shares Filed |
6.0M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
6.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$45.0M |
| · % Change from Original |
-42.31 |
| File Price Range |
$8.00 - $7.00 |
| File Mid Price |
$7.50 |
|
